Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,363 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07062055RecruitingPhase 2
Combination therapy for advanced liver cancer that has spread
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
Jinan, ShandongAges 18–70 - NCT07064018RecruitingPhase 1/Phase 2
SPEDOX-6 for advanced solid tumors
This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.
Orange, CaliforniaAges 18 years+ - NCT07058948RecruitingPhase 2
Combining special radiation with immunotherapy for advanced cancer
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07063693RecruitingPhase 1
ABY-029 imaging for high-grade glioma surgery
This trial tests a new imaging agent called ABY-029 during surgery for high-grade glioma (a type of brain tumor). It helps doctors see the tumor more clearly, which may improve removal.
Lebanon, New HampshireAges 18 years+ - NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07050641RecruitingPhase 1/Phase 2
Study of SCTB39-1 for advanced solid tumors
This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.
BeijingAges 18 years+ - NCT06991946Recruiting
Genomic profiling for metastatic breast cancer in Spain
This study looks at how genetic testing of your tumor might affect the treatment plan for your metastatic breast cancer. It aims to help doctors choose the best therapy based on your tumor's profile.
Barcelona, BarcelonaAges 18 years+ - NCT07047573Recruiting
Better testing for lung nodules to tell benign from cancer
This study uses advanced testing methods on lung nodules to better tell if they are benign (not cancer) or malignant (cancer). It may help improve diagnosis for people scheduled for surgery to remove a lung nodule.
Suzhou, JiangsuAges Any age - NCT07053462RecruitingPhase 1/Phase 2
Gene-edited kidney transplant to lower rejection risk
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
Beijing, ChangpingAges 16–85 - NCT07049094RecruitingPhase 4
Scalp nerve block for pain after brain surgery
This trial tests if a long-lasting numbing medicine (bupivacaine liposomes) injected into scalp nerves can reduce pain after brain surgery. It may help you need less pain medicine and feel better after your operation.
Hangzhou, ZhejiangAges 18 years+ - NCT06992336RecruitingPhase 2
Circulating tumor DNA guided extra treatment for early triple-negative breast cancer
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
Guangzhou, GuangodngAges 18–70 - NCT07039474Recruiting
New PET scan to monitor cancer immunotherapy response
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
BeijingAges 18–75 - NCT07035938Recruiting
T-Cell Health in Blood Cancer Patients Study
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
Xiamen, FujianAges 18 years+ - NCT07035587Recruiting
A blood test to detect multiple cancers and monitor leftover tumors after treatment
This trial uses a blood test to find early signs of cancer or leftover tumor cells after treatment. It may help people with certain cancers or those with non-cancerous growths understand their condition better.
SeoulAges 19 years+ - NCT07043608RecruitingPhase 2
Zanzalintinib for kidney cancer that spread to bone
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
San Francisco, CaliforniaAges 18 years+ - NCT07038733Recruiting
Lymph node study for kidney cancer patients
This study looks at lymph nodes in people with known or suspected kidney cancer to learn more about the disease. It may help researchers understand how kidney cancer affects the lymph system.
New Haven, ConnecticutAges 18 years+ - NCT07034339Recruiting
Immune map for pancreatic cancer evolution
This study builds an immune map of how pancreatic cancer changes over time. It may help doctors better understand the disease and find new treatment strategies.
Hangzhou, ZhejiangAges 18–80 - NCT07041229Enrolling by invitation
Comparing two ways to remove large colon polyps
This trial is for people with large (20-60 mm), non-cancerous colon growths on a wide base. It compares two endoscopic removal methods—ESD and EMR—to see which works best.
MoscowAges 18–100 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT05867004Recruiting
Block TNF to boost immune response in melanoma
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
ToulouseAges 18 years+ - NCT07030712RecruitingPhase 1
Study of MK-8294 for advanced solid tumors
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
Chicago, IllinoisAges 18 years+ - NCT06956144Recruiting
CAIX-targeted PET scan for kidney cancer
This trial uses a special PET scan that targets a protein (CAIX) often found in kidney cancer cells. It helps doctors see the cancer more clearly, which may guide better treatment decisions.
XiamenAges 18–74 - NCT07026370Enrolling by invitation
Chinese Health Study: Long-term health follow-up
This study is following up with people who already took part in a large health survey in China. It looks at how multiple health conditions develop over time and why some people stay healthier than others.
Beijing, Beijing MunicipalityAges 20 years+ - NCT07023848Enrolling by invitationEarly Phase 1
Imaging study for HER2-positive cancers using a special tracer
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
Wuxi, JiangsuAges 18–75
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,363 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.